Without a prescribed development process or the potential to reference the pathway pioneered by a previously approved orthopedic combination product, consistent and close interaction with regulatory authorities was important. In the early 1990s, the uncertain regulatory process for combination products meant that the way forward was occasionally determined as the project moved through the development and review process. Other testing needs were identified based on the nature of the protein being studied, along with considerations of the intended indications. During development, it was clear that both typical systemic toxicology testing for drugs and biocompatibility testing for devices would be required. The dual nature of the product, combining a drug and a device, led to a development pathway that was extraordinarily complicated, with many opportunities for missteps along the way. Feel free to give us a call.INFUSE ® Bone Graft is a combination product consisting of a recombinant version of a naturally occurring protein for bone healing and regeneration and an absorbable carrier matrix. Borchardt Law Firm represent clients all across the country to settle cases regarding improper use of medical devices. If you are a loved one has encountered a situation like this, call us for a free consultation. The misuse of a medical device can be extremely risky. Please call for a free consultation to ensure that you or a loved one is getting the best health care service possible. Do not let a situation like this be ignored. If you have received an INFUSE Bone Graft or know of someone who has they could have symptoms similar to the ones above. Situations like this one or very similar can result in unfortunate situations that no one should encounter. These symptoms occur two to fourteen days after surgery. The use of this Bone Graft incorrectly can lead to swelling of the airways resulting in difficulty breathing, swallowing or speaking, respiratory depression, nerve damage, male sterility, formation of inflammatory cysts, unwanted bone growth, and even death. These physicians did not notify their patients of the risks that come with using “off-label.” Some physicians who were using the INFUSE Bone Graft in ways that were not approved by the FDA, received payments from Medtronic to use the Bone Graft. Once the patient gives consent they may risk their life in order to use the “off label” product. When an “off-label” is used by physicians, they must relay all of the risks and complications that may come with the “off-label” product prior to the surgery. The use of the INFUSE Bone Graft generated more than $3 billion in sales for Medtronic. The “off-label” use that physicians were implementing was not approved by the FDA. Medtronic allegedly promoted and encouraged its use in other types of spinal surgeries including thoracic fusion, cervical fusion, posterior lumbar fusion and multilevel fusion. Not long after the FDA came out with the Safety Communication warning, Medtronic paid $85 million in lawsuits by shareholders because Medtronic did not release information regarding the INFUSE Bone Graft that mislead people in the use of the product. In 2008 FDA published a Safety Communication warning of life threatening complications associated with the use of the INFUSE Bone Graft in cervical spine areas. In 2004 the FDA approved the INFUSE Bone Graft for various types of tibia fractures in the lower leg. In 2002 the FDA approved the INFUSE Bone Graft only for the treatment of degenerative disc disease. The INFUSE Bone Graft has been approved gradually by the FDA regarding the procedures that are compatible with the INFUSE Bone Graft. The sponge then dissolves and is absorbed into the body. The device is put between vertebrae and stimulates the bone growth. This genetically engineered protein helps build bone tissue in the fusion process, instead of using a graft of the patient’s own bone. It has a sponge-type substance that is soaked in the biological fluid which is a type of synthetic liquid bone morphogenic protein. The INFUSE Bone Graft consists of two parts. The INFUSE Bone Graft generally treats degenerative disc disease however it has been used in other inappropriate ways. The INFUSE Bone Graft is an alternative to traditional bone graft because it prevents from painful harvesting of other parts in the body. The Medtronic INFUSE Bone Graft is a device that is implanted after lower back surgery to stimulate bone growth in an area of implantation. Over the past few years the Medtronic INFUSE Bone Graft has raised many issues and resulted in large amounts of lawsuits.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |